This is a preview of subscription content
Subscription info for Chinese customers
We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Doki, Y. et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 386, 449–462 (2022)
About this article
Cite this article
Killock, D. Frontline nivolumab combinations improve OS in ESCC. Nat Rev Clin Oncol 19, 219 (2022). https://doi.org/10.1038/s41571-022-00608-2